{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T07:38:43Z","timestamp":1792395523824,"version":"4.4.0"},"reference-count":201,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing has begun to transform the treatment landscape of genetic diseases. The history of the discovery of CRISPR\/CRISPR-associated (Cas) proteins\/single-guide RNA (sgRNA)-based gene editing since the first report of repetitive sequences of unknown significance in 1987 is fascinating, highly instructive, and inspiring for future advances in medicine. The recent approval of CRISPR-Cas9-based gene therapy to treat patients with severe sickle cell anemia and transfusion-dependent \u03b2-thalassemia has renewed hope for treating other hematologic diseases, including patients with a germline predisposition to hematologic malignancies, who would benefit greatly from the development of CRISPR-inspired gene therapies. The purpose of this paper is three-fold: first, a chronological description of the history of CRISPR-Cas9-sgRNA-based gene editing; second, a brief description of the current state of clinical research in hematologic diseases, including selected applications in treating hematologic diseases with CRISPR-based gene therapy, preceded by a brief description of the current tools being used in clinical genome editing; and third, a presentation of the current progress in gene therapies in inherited hematologic diseases and bone marrow failure syndromes, to hopefully stimulate efforts towards developing these therapies for patients with inherited bone marrow failure syndromes and other inherited conditions with a germline predisposition to hematologic malignancies.<\/jats:p>","DOI":"10.3390\/genes15070863","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T06:04:18Z","timestamp":1719986658000},"page":"863","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The CRISPR-Cas System and Clinical Applications of CRISPR-Based Gene Editing in Hematology with a Focus on Inherited Germline Predisposition to Hematologic Malignancies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4289-3057","authenticated-orcid":false,"given":"Rina","family":"Kansal","sequence":"first","affiliation":[{"name":"Molecular Oncology and Genetics, Diagnostic Laboratories, Versiti Blood Center of Wisconsin, Milwaukee, WI 53233, USA"},{"name":"Department of Pathology and Anatomical Sciences, The University at Buffalo, Buffalo, NY 14260, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/495050a","article-title":"Biotechnology: Rewriting a genome","volume":"495","author":"Charpentier","year":"2013","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.aat5011","article-title":"CRISPR-Cas guides the future of genetic engineering","volume":"361","author":"Knott","year":"2018","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR technology: A decade of genome editing is only the beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_7","unstructured":"New York State Department of Health (2024, June 22). The Need for Blood Stem Cell Donors, Available online: https:\/\/www.health.ny.gov\/professionals\/patients\/donation\/bone_marrow\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.stem.2017.10.010","article-title":"Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned","volume":"21","author":"Morgan","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_10","unstructured":"(2024, June 22). National Marrow Donor Program. Available online: https:\/\/bethematch.org\/transplant-basics\/how-blood-stem-cell-transplants-work\/how-does-a-patients-ethnic-background-affect-matching\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/s41409-022-01736-0","article-title":"Disease progression, hospital readmissions, and clinical outcomes for patients with steroid-refractory acute graft-versus-host disease: A multicenter, retrospective study","volume":"57","author":"Holtan","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: A report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: An updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv."},{"key":"ref_17","unstructured":"The UK Medicines and Healthcare Products Regulatory Agency Press Release (2024, June 22). MHRA Authorises World-First Gene Therapy That Aims to Cure Sickle-Cell Disease and Transfusion-Dependent \u03b2-Thalassemia. 16 November 2023, Available online: https:\/\/www.gov.uk\/government\/news\/mhra-authorises-world-first-gene-therapy-that-aims-to-cure-sickle-cell-disease-and-transfusion-dependent-thalassemia."},{"key":"ref_18","unstructured":"U.S. Food and Drug Administration News Release (2024, May 30). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. 8 December 2023, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease."},{"key":"ref_19","unstructured":"The European Medicines Agency (EMA) (2024, June 22). First Gene Editing Therapy to Treat Beta Thalassemia and Severe Sickle Cell Disease. 15 December 2024, Available online: https:\/\/www.ema.europa.eu\/en\/news\/first-gene-editing-therapy-treat-beta-thalassemia-and-severe-sickle-cell-disease%20Accessed%20June%2022."},{"key":"ref_20","unstructured":"Rezaei, N. (2024). Germline predisposition in hematologic malignancies. Comprehensive Hematology and Stem Cell Research, Elsevier. In press."},{"key":"ref_21","unstructured":"Kansal, R. (2024). Inherited germline predisposition in hematologic malignancy. Acute Myeloid Leukemia: Diagnosis, Prognosis, Treatment and Outcomes, Nova Science Publishers, Inc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: Continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2022","journal-title":"Haematologica"},{"key":"ref_23","first-page":"e1","article-title":"An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"29","author":"Tokaz","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ymthe.2024.03.037","article-title":"CRISPR-Cas9n-mediated ELANE promoter editing for gene therapy of severe congenital neutropenia","volume":"32","author":"Nasri","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J. Bacteriol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2958.1993.tb01721.x","article-title":"Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites","volume":"9","author":"Mojica","year":"1993","journal-title":"Mol. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2958.1995.mmi_17010085.x","article-title":"Long stretches of short tandem repeats are present in the largest replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and could be involved in replicon partitioning","volume":"17","author":"Mojica","year":"1995","journal-title":"Mol. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1111\/febs.13766","article-title":"The discovery of CRISPR in archaea and bacteria","volume":"283","author":"Mojica","year":"2016","journal-title":"FEBS J."},{"key":"ref_29","unstructured":"Rodriguez-Fernandez, C. (2024, May 22). Francis Mojica, the Spanish Scientist Who Discovered CRISPR. Labiotech. 8 April 2019, Updated 23 June 2022. Available online: https:\/\/www.labiotech.eu\/interview\/francis-mojica-crispr-interview\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen","year":"2002","journal-title":"Mol. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00580-17","DOI":"10.1128\/JB.00580-17","article-title":"History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology","volume":"200","author":"Ishino","year":"2018","journal-title":"J. Bacteriol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Haft, D.H., Selengut, J., Mongodin, E.F., and Nelson, K.E. (2005). A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR\/Cas subtypes exist in prokaryotic genomes. PLoS Comput. Biol., 1.","DOI":"10.1371\/journal.pcbi.0010060"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00239-004-0046-3","article-title":"Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements","volume":"60","author":"Mojica","year":"2005","journal-title":"J. Mol. Evol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/mic.0.27437-0","article-title":"CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies","volume":"151","author":"Pourcel","year":"2005","journal-title":"Microbiology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1099\/mic.0.28048-0","article-title":"Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin","volume":"151","author":"Bolotin","year":"2005","journal-title":"Microbiology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/JB.01415-07","article-title":"Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus","volume":"190","author":"Horvath","year":"2008","journal-title":"J. Bacteriol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1126\/science.1159689","article-title":"Small CRISPR RNAs guide antiviral defense in prokaryotes","volume":"321","author":"Brouns","year":"2008","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1101\/gad.1742908","article-title":"Cas6 is an endoribonuclease that generates guide RNAs for invader defense in prokaryotes","volume":"22","author":"Carte","year":"2008","journal-title":"Genes. Dev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1261\/rna.2230110","article-title":"Binding and cleavage of CRISPR RNA by Cas6","volume":"16","author":"Carte","year":"2010","journal-title":"RNA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1126\/science.1165771","article-title":"CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA","volume":"322","author":"Marraffini","year":"2008","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrmicro1325","article-title":"Antimicrobial-resistant bacteria in the community setting","volume":"4","author":"Furuya","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1099\/mic.0.023960-0","article-title":"Short motif sequences determine the targets of the prokaryotic CRISPR defence system","volume":"155","author":"Mojica","year":"2009","journal-title":"Microbiology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tibs.2009.05.002","article-title":"CRISPR-based adaptive and heritable immunity in prokaryotes","volume":"34","author":"Jore","year":"2009","journal-title":"Trends Biochem. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature09523","article-title":"The CRISPR\/Cas bacterial immune system cleaves bacteriophage and plasmid DNA","volume":"468","author":"Garneau","year":"2010","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/468045a","article-title":"Microbiology: Slicer for DNA","volume":"468","author":"Sontheimer","year":"2010","journal-title":"Nature"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.1192272","article-title":"Sequence- and structure-specific RNA processing by a CRISPR endonuclease","volume":"329","author":"Haurwitz","year":"2010","journal-title":"Science"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1261\/rna.030882.111","article-title":"Mechanism of substrate selection by a highly specific CRISPR endoribonuclease","volume":"18","author":"Sternberg","year":"2012","journal-title":"RNA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/532432a","article-title":"The quiet revolutionary: How the co-discovery of CRISPR explosively changed Emmanuelle Charpentier\u2019s life","volume":"532","author":"Abbott","year":"2016","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature09886","article-title":"CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III","volume":"471","author":"Deltcheva","year":"2011","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrmicro2577","article-title":"Evolution and classification of the CRISPR-Cas systems","volume":"9","author":"Makarova","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/d41586-020-02765-9","article-title":"Pioneers of revolutionary CRISPR gene editing win chemistry Nobel","volume":"586","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9275","DOI":"10.1093\/nar\/gkr606","article-title":"The Streptococcus thermophilus CRISPR\/Cas system provides immunity in Escherichia coli","volume":"39","author":"Sapranauskas","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature13011","article-title":"DNA interrogation by the CRISPR RNA-guided endonuclease Cas9","volume":"507","author":"Sternberg","year":"2014","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nbt.2527","article-title":"RNA guides genome engineering","volume":"31","author":"Mussolino","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e00471","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"Elife"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.stem.2013.10.016","article-title":"Correction of a genetic disease in mouse via use of CRISPR-Cas9","volume":"13","author":"Wu","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2014.02.001","article-title":"Crystal structure of Cas9 in complex with guide RNA and target DNA","volume":"156","author":"Nishimasu","year":"2014","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nsmb.2820","article-title":"Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity","volume":"21","author":"Kranzusch","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nature14237","article-title":"Integrase-mediated spacer acquisition during CRISPR-Cas adaptive immunity","volume":"519","author":"Lee","year":"2015","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1247023","article-title":"Microbiology. Genomes from metagenomics","volume":"342","author":"Sharon","year":"2013","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.cell.2015.09.038","article-title":"Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system","volume":"163","author":"Zetsche","year":"2015","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molcel.2015.10.008","article-title":"Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems","volume":"60","author":"Shmakov","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"aaf5573","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nature19802","article-title":"Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection","volume":"538","author":"Knight","year":"2016","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature21059","article-title":"New CRISPR-Cas systems from uncultivated microbes","volume":"542","author":"Burstein","year":"2017","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrmicro.2016.184","article-title":"Diversity and evolution of class 2 CRISPR-Cas systems","volume":"15","author":"Shmakov","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mib.2017.05.008","article-title":"Diversity, classification and evolution of CRISPR-Cas systems","volume":"37","author":"Koonin","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2018.02.028","article-title":"Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein","volume":"70","author":"Yan","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.aav4294","article-title":"Programmed DNA destruction by miniature CRISPR-Cas14 enzymes","volume":"362","author":"Harrington","year":"2018","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.aav7271","article-title":"Functionally diverse type V CRISPR-Cas systems","volume":"363","author":"Yan","year":"2019","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2017.09.007","article-title":"The Revolution Continues: Newly Discovered Systems Expand the CRISPR-Cas Toolkit","volume":"68","author":"Murugan","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrmicro3569","article-title":"An updated evolutionary classification of CRISPR-Cas systems","volume":"13","author":"Makarova","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41579-019-0299-x","article-title":"Evolutionary classification of CRISPR-Cas systems: A burst of class 2 and derived variants","volume":"18","author":"Makarova","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/10409238.2020.1856769","article-title":"HEPN RNases\u2014An emerging class of functionally distinct RNA processing and degradation enzymes","volume":"56","author":"Pillon","year":"2021","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41556-019-0425-z","article-title":"Advances in genome editing through control of DNA repair pathways","volume":"21","author":"Yeh","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Yang, H., Ren, S., Yu, S., Pan, H., Li, T., Ge, S., Zhang, J., and Xia, N. (2020). Methods Favoring Homology-Directed Repair Choice in Response to CRISPR\/Cas9 Induced-Double Strand Breaks. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186461"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cell"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/d41586-019-03164-5","article-title":"Super-precise new CRISPR tool could tackle a plethora of genetic diseases","volume":"574","author":"Ledford","year":"2019","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","article-title":"The next generation of CRISPR-Cas technologies and applications","volume":"20","author":"Gersbach","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jama.2022.13468","article-title":"Treatment of Genetic Diseases With CRISPR Genome Editing","volume":"328","author":"Kan","year":"2022","journal-title":"JAMA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/d41586-023-03797-7","article-title":"CRISPR 2.0: A new wave of gene editors heads for clinical trials","volume":"624","author":"Ledford","year":"2023","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1038\/s41467-020-17626-2","article-title":"Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott-Aldrich Syndrome","volume":"11","author":"Rai","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","article-title":"Lentiviral Gene Therapy for Artemis-Deficient SCID","volume":"387","author":"Cowan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/d41573-020-00096-y","article-title":"Gene-editing pipeline takes off","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"(2011). Move over ZFNs. Nat. Biotechnol., 29, 681\u2013684.","DOI":"10.1038\/nbt.1935"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nmeth0311-197","article-title":"TALEs for the masses","volume":"8","author":"Rusk","year":"2011","journal-title":"Nat. Methods"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1073\/pnas.95.18.10564","article-title":"Structure of FokI has implications for DNA cleavage","volume":"95","author":"Wah","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/528469a","article-title":"Genome-editing revolution: My whirlwind year with CRISPR","volume":"528","author":"Doudna","year":"2015","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1126\/science.aab1028","article-title":"Biotechnology. A prudent path forward for genomic engineering and germline gene modification","volume":"348","author":"Baltimore","year":"2015","journal-title":"Science"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/d41573-022-00124-z","article-title":"Base editors hit the clinic","volume":"21","author":"Kingwell","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"dmm049857","DOI":"10.1242\/dmm.049857","article-title":"Hacking hematopoiesis\u2014Emerging tools for examining variant effects","volume":"16","author":"Gundry","year":"2023","journal-title":"Dis. Model. Mech."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kansal, R. (2023). Novel immunotherapies in hematologic and non-hematologic cancers. Precision Medicine: Where Are We And Where Are We Going?, Nova Science Publishers, Inc.","DOI":"10.52305\/WQEQ5178"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e20231235","DOI":"10.1084\/jem.20231235","article-title":"Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy","volume":"220","author":"Marone","year":"2023","journal-title":"J. Exp. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry B Clin. Cytom."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cell.2023.02.027","article-title":"Human T cell generation is restored in CD3\u03b4 severe combined immunodeficiency through adenine base editing","volume":"186","author":"McAuley","year":"2023","journal-title":"Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle Cell Disease","volume":"376","author":"Piel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0140-6736(22)00536-0","article-title":"Thalassaemia","volume":"399","author":"Kattamis","year":"2022","journal-title":"Lancet"},{"key":"ref_116","unstructured":"National Center for Biotechnology Information (2024, June 25). A Study Evaluating the Safety and Efficacy of bb1111 in Severe Sickle Cell Disease. #NCT02140554, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02140554#study-overview."},{"key":"ref_117","unstructured":"Bluebird Bio Inc. (2024, June 25). LyfgeniaTM (Lovotibeglogene Autotemcel) U.S. Resident Website. Studies and Results. Available online: https:\/\/www.lyfgenia.com\/clinical-trial-results."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.gde.2015.08.001","article-title":"Hemoglobin switching\u2019s surprise: The versatile transcription factor BCL11A is a master repressor of fetal hemoglobin","volume":"33","author":"Bauer","year":"2015","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_119","unstructured":"(2024, May 31). Vertex Pharmaceuticals Incorporated Website for Casgevy. Available online: https:\/\/www.casgevy.com\/."},{"key":"ref_120","unstructured":"Stein, R. (2024, May 03). Sickle Cell Patient\u2019s Success with Gene Editing Raises Hopes and Questions. Available online: https:\/\/www.npr.org\/sections\/health-shots\/2023\/03\/16\/1163104822\/crispr-gene-editing-sickle-cell-success-cost-ethics."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1073\/pnas.1612075113","article-title":"Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and \u03b2-thalassemia","volume":"113","author":"Ye","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"ref_123","first-page":"2085","article-title":"In vivo HSC prime editing rescues sickle cell disease in a mouse model","volume":"141","author":"Li","year":"2023","journal-title":"Blood"},{"key":"ref_124","unstructured":"National Library of Medicine Clinical Trials website (2024, June 04). EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants with Transfusion-Dependent Beta Thalassemia (TDT), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05444894."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_126","unstructured":"(2024). FDA clears prime editors for testing in humans. Nat. Biotechnol., 42."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41572-019-0113-0","article-title":"Chromosome instability syndromes","volume":"5","author":"Taylor","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.2021.279981","article-title":"Genotype-phenotype and outcome associations in patients with Fanconi anemia: The National Cancer Institute cohort","volume":"108","author":"Altintas","year":"2023","journal-title":"Haematologica"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S2352-3026(24)00063-2","article-title":"Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: International consensus statement","volume":"11","author":"Wlodarski","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood.2019000947","article-title":"Diamond-Blackfan anemia","volume":"136","author":"Leblanc","year":"2020","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-023-02101-w","article-title":"Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia","volume":"38","author":"Liu","year":"2024","journal-title":"Leukemia"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jbior.2017.09.002","article-title":"Molecular basis of the human ribosomopathy Shwachman-Diamond syndrome","volume":"67","author":"Warren","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2022017739","article-title":"Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: Biological insights and clinical advances","volume":"141","author":"Reilly","year":"2023","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3324\/haematol.2023.282949","article-title":"Shwachman-Diamond syndromes: Clinical, genetic, and biochemical insights from the rare variants","volume":"108","author":"Kawashima","year":"2023","journal-title":"Haematologica"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/17474086.2022.2108784","article-title":"The biology and management of dyskeratosis congenita and related disorders of telomeres","volume":"15","author":"Tummala","year":"2022","journal-title":"Expert. Rev. Hematol."},{"key":"ref_136","unstructured":"Team Telomere\u2014An International Community for Telomere Biology Disorders (2022). Telomere Biology Disorders: Diagnosis and Management Guidelines, Team Telomere. [2nd ed.]. Available online: https:\/\/teamtelomere.org\/diagnosis-management-guidelines."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/hematology.2021000286","article-title":"Impaired myelopoiesis in congenital neutropenia: Insights into clonal and malignant hematopoiesis","volume":"2021","author":"Warren","year":"2021","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/hematology.2022000392","article-title":"Genetics of severe congenital neutropenia as a gateway to personalized therapy","volume":"2022","author":"Donadieu","year":"2022","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2022.282024","article-title":"The name counts: The case of \u2018congenital amegakaryocytic thrombocytopenia\u2019","volume":"108","author":"Balduini","year":"2023","journal-title":"Haematologica"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"101286","DOI":"10.1016\/j.beha.2021.101286","article-title":"Congenital amegakaryocytic thrombocytopenia\u2014Not a single disease","volume":"34","author":"Germeshausen","year":"2021","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2017-09-806489","article-title":"A landscape of germ line mutations in a cohort of inherited bone marrow failure patients","volume":"131","author":"Bluteau","year":"2018","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00277-023-05128-2","article-title":"ERCC6L2-related disease: A novel entity of bone marrow failure disorder with high risk of clonal evolution","volume":"102","author":"Baccelli","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_143","first-page":"2853","article-title":"The clinical picture of ERCC6L2 disease: From bone marrow failure to acute leukemia","volume":"141","author":"Hakkarainen","year":"2023","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","article-title":"Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","volume":"28","author":"Frebourg","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S1470-2045(21)00580-5","article-title":"Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: An observational cohort study","volume":"22","author":"Khincha","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Rocca, V., Blandino, G., D\u2019Antona, L., Iuliano, R., and Di Agostino, S. (2022). Li-Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment. Cancers, 14.","DOI":"10.3390\/cancers14153664"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Sandner, A.S., Weggel, R., Mehraein, Y., Schneider, S., Hiddemann, W., and Spiekermann, K. (2019). Frequency of hematologic and solid malignancies in the family history of 50 patients with acute myeloid leukemia\u2014A single center analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215453"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/jmedgenet-2020-107627","article-title":"Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): Recommendations from the international consensus working group","volume":"59","author":"Aronson","year":"2022","journal-title":"J. Med. Genet."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41698-024-00603-z","article-title":"Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants","volume":"8","author":"Gallon","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"ref_150","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., and Amemiya, A. (2023). Bloom Syndrome. [updated 2023 Oct 12]. GeneReviews\u00ae [Internet], University of Washington."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.arr.2016.03.002","article-title":"Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions","volume":"33","author":"Oshima","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Lauper, J.M., Krause, A., Vaughan, T.L., and Monnat, R.J. (2013). Spectrum and risk of neoplasia in Werner syndrome: A systematic review. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059709"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Petley, E., Yule, A., Alexander, S., Ojha, S., and Whitehouse, W.P. (2022). The natural history of ataxia-telangiectasia (A-T): A systematic review. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264177"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1182\/bloodadvances.2023009742","article-title":"Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome","volume":"7","author":"Guijarro","year":"2023","journal-title":"Blood Adv."},{"key":"ref_155","unstructured":"Riboldi, G.M., Samanta, D., Asuncion, R.M.D., and Frucht, S. (2024). Ataxia-Telangiectasia. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Elitzur, S., Shiloh, R., Loeffen, J.L.C., Pastorczak, A., Takagi, M., Bomken, S., Baruchel, A., Lehrnbecher, T., Tasian, S.K., and Abla, O. (2024). ATM germline pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies. Blood, Online ahead of print.","DOI":"10.1182\/blood.2024024283"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-016-0520-1","article-title":"DNA ligase IV syndrome; a review","volume":"11","author":"Altmann","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Schober, S., Schilbach, K., Doering, M., Cabanillas Stanchi, K.M., Holzer, U., Kasteleiner, P., Schittenhelm, J., Schaefer, J.F., Mueller, I., and Lang, P. (2019). Allogeneic hematopoietic stem cell transplantation in two brothers with DNA ligase IV deficiency: A case report and review of the literature. BMC Pediatr., 19.","DOI":"10.1186\/s12887-019-1851-6"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bj.2021.06.004","article-title":"RASopathies: From germline mutations to somatic and multigenic diseases","volume":"44","author":"Riller","year":"2021","journal-title":"Biomed. J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/bloodadvances.2021005117","article-title":"Juvenile myelomonocytic leukemia in the molecular era: A clinician\u2019s guide to diagnosis, risk stratification, and treatment","volume":"5","author":"Wintering","year":"2021","journal-title":"Blood Adv."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3324\/haematol.2020.270595","article-title":"Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia","volume":"107","author":"Hecht","year":"2022","journal-title":"Haematologica"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/85820","article-title":"Dominant-negative mutations of CEBPA, encoding CCAAT\/enhancer binding protein-alpha (C\/EBPalpha), in acute myeloid leukemia","volume":"27","author":"Pabst","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.2020009652","article-title":"CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: A report from the Children\u2019s Oncology Group","volume":"138","author":"Tarlock","year":"2021","journal-title":"Blood"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"107453","DOI":"10.1016\/j.leukres.2024.107453","article-title":"Clinical features and management of germline CEBPA-mutated carriers","volume":"138","author":"Pan","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","article-title":"RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.3324\/haematol.2021.278762","article-title":"The RUNX1 database (RUNX1db): Establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy","volume":"106","author":"Homan","year":"2021","journal-title":"Haematologica"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"100784","DOI":"10.1016\/j.blre.2020.100784","article-title":"Inherited thrombocytopenias: An updated guide for clinicians","volume":"48","author":"Pecci","year":"2021","journal-title":"Blood Rev."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022017735","article-title":"Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26","volume":"141","author":"Homan","year":"2023","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI71861","article-title":"Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation","volume":"124","author":"Bluteau","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3324\/haematol.2016.147496","article-title":"Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia","volume":"101","author":"Melazzini","year":"2016","journal-title":"Haematologica"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/s41375-022-01708-9","article-title":"DDX41 coordinates RNA splicing and transcriptional elongation to prevent DNA replication stress in hematopoietic cells","volume":"36","author":"Shinriki","year":"2022","journal-title":"Leukemia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bjh.18848","article-title":"Causative germline variant p.Y259C of DDX41 recurrently identified in acute lymphoblastic leukaemia","volume":"202","author":"Huo","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood.2023020209","article-title":"Prevalence and significance of DDX41 gene variants in the general population","volume":"142","author":"Gu","year":"2023","journal-title":"Blood"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/BST20230725","article-title":"DDX41: Exploring the roles of a versatile helicase","volume":"52","author":"Winstone","year":"2024","journal-title":"Biochem. Soc. Trans."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2011.04.007","article-title":"The role of the GATA2 transcription factor in normal and malignant hematopoiesis","volume":"82","author":"Vicente","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/humu.24271","article-title":"GATA2 deficiency syndrome: A decade of discovery","volume":"42","author":"Homan","year":"2021","journal-title":"Hum. Mutat."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Santiago, M., Liquori, A., Such, E., Z\u00fa\u00f1iga, \u00c1., and Cervera, J. (2023). The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency. Cancers, 15.","DOI":"10.3390\/cancers15051590"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41591-021-01511-6","article-title":"Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9\/SAMD9L syndromes","volume":"27","author":"Sahoo","year":"2021","journal-title":"Nat. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e15283","DOI":"10.1111\/ped.15283","article-title":"Discovery of MIRAGE syndrome","volume":"64","author":"Narumi","year":"2022","journal-title":"Pediatr. Int."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1080\/10428194.2021.1929966","article-title":"Donor derived leukemia in allogeneic transplantation","volume":"62","author":"Aldoss","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1182\/blood-2010-12-326322","article-title":"First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"117","author":"Xiao","year":"2011","journal-title":"Blood"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2016.310","article-title":"Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation","volume":"31","author":"Berger","year":"2017","journal-title":"Leukemia"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/leu.2017.44","article-title":"Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogeneic hematopoietic stem cell transplantation","volume":"31","author":"Kobayashi","year":"2017","journal-title":"Leukemia"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-023-00846-2","article-title":"DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation","volume":"13","author":"Rolles","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.2020006481","article-title":"Inherited bone marrow failure in the pediatric patient","volume":"140","author":"Dokal","year":"2022","journal-title":"Blood"},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Vissers, L.T.W., van der Burg, M., Lankester, A.C., Smiers, F.J.W., Bartels, M., and Mohseny, A.B. (2023). Pediatric Bone Marrow Failure: A Broad Landscape in Need of Personalized Management. J. Clin. Med., 12.","DOI":"10.3390\/jcm12227185"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41591-019-0550-z","article-title":"Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia","volume":"25","author":"Navarro","year":"2019","journal-title":"Nat. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e171650","DOI":"10.1172\/jci.insight.171650","article-title":"Lentivirus-mediated gene therapy corrects ribosomal biogenesis and shows promise for Diamond Blackfan anemia","volume":"9","author":"Palacios","year":"2024","journal-title":"JCI Insight"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1038\/s41467-022-34479-z","article-title":"Adenine base editing efficiently restores the function of Fanconi anemia hematopoietic stem and progenitor cells","volume":"13","author":"Siegner","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","article-title":"Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity","volume":"38","author":"Richter","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41418-022-00996-z","article-title":"Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?","volume":"29","author":"Thomas","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1898523","DOI":"10.1080\/23723556.2021.1898523","article-title":"Zmat3 splices together p53-dependent tumor suppression","volume":"8","author":"Attardi","year":"2021","journal-title":"Mol. Cell Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41418-023-01250-w","article-title":"Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice","volume":"31","author":"Brennan","year":"2024","journal-title":"Cell Death Differ."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/10409238.2024.2344465","article-title":"Elucidating the chain of command: Our current understanding of critical target genes for p53-mediated tumor suppression","volume":"59","author":"Indeglia","year":"2024","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bjh.18682","article-title":"Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT)","volume":"201","author":"Clark","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bbmt.2020.02.015","article-title":"Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations","volume":"26","author":"Hofmann","year":"2020","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/7\/863\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:08:29Z","timestamp":1760108909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/15\/7\/863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":201,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["genes15070863"],"URL":"https:\/\/doi.org\/10.3390\/genes15070863","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}